← All trials
NCT05901012
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 26, 2023
- Primary completion
- Jul 17, 2023
- Completion date
- Jul 17, 2023
- First posted
- Jun 13, 2023
- Last posted
- Oct 11, 2023
- Enrollment
- 25
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Universidade Federal do Rio Grande do NorteLead sponsor
- Universidade Federal do Rio Grande do NorteOverall official - principal investigator
- Universidade Federal do Rio Grande do NorteReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.